This is set to happen because the biopharma's commercialization partner recently terminated its agreement over the product, noted an H.C. Wainwright & Co. report.
IRadimed Corp. reported Q2/22 financial results that were modestly higher than expected. ROTH Capital Partners LLC advised in a research update that based on the company's higher revenues, improved margins, and disciplined cost control measures it is maintaining its Buy rating on IRadimed and raising its price target to $42/share (up from $40).